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One genome, many epigenomes
Embryonic stem cells (ESCs) and the early developmental 
stage embryo share a unique property called pluripotency, 
which is the ability to give rise to the three germ layers 
(endoderm, ectoderm and mesoderm) and, consequently, 
all  tissues  represented  in  the  adult  organism  [1,2]. 
Pluripotency can also be induced in somatic cells during in 
vitro reprogramming, leading to the formation of so-called 
induced pluripotent stem cells (iPSCs; extensively reviewed 
in [3-7]). In order to fulfill the therapeutic potential of 
human ESCs (hESCs) and iPSCs, an understanding of the 
fundamental molecular properties underlying the nature 
of pluripotency and commitment is required, along with 
the  development  of  methods  for  assessing  biological 
equivalency among different cell populations.
Functional complexity of the human body, with over 
200 specialized cell types, and intricately built tissues and 
organs, arises from a single set of instructions: the human 
genome.  How,  then,  do  distinct  cellular  phenotypes 
emerge  from  this  genetic  homogeneity?  Interactions 
between  the  genome  and  its  cellular  and  signaling 
environments  are  the  key  to  understanding  how  cell-
type-specific  gene  expression  patterns  arise  during 
differentiation and development [8]. These interactions 
ultimately  occur  at  the  level  of  the  chromatin,  which 
comprises the DNA polymer repeatedly wrapped around 
histone  octamers,  forming  a  nucleosomal  array  that  is 
further  compacted  into  the  higher-order  structure. 
Regulatory variation is introduced to the chromatin via 
alterations within the nucleosome itself – for example, 
through  methylation  and  hydroxymethylation  of  DNA, 
various  post-translational  modifications  (PTMs)  of 
histones, and inclusion or exclusion of specific histone 
variants [9-15] – as well as via changes in nucleosomal 
occupancy,  mobility  and  organization  [16,17].  In  turn, 
these alterations modulate access of sequence-dependent 
transcriptional  regulators  to  the  underlying  DNA,  the 
level  of  chromatin  compaction,  and  communication 
between distant chromosomal regions [18]. The entirety 
of  chromatin  regulatory  variation  in  a  specific  cellular 
state is often referred to as the ‘epigenome’ [19].
Abstract
Human pluripotent cells such as human embryonic 
stem cells (hESCs) and induced pluripotent stem 
cells (iPSCs) and their in vitro differentiation models 
hold great promise for regenerative medicine 
as they provide both a model for investigating 
mechanisms underlying human development and 
disease and a potential source of replacement cells in 
cellular transplantation approaches. The remarkable 
developmental plasticity of pluripotent cells is reflected 
in their unique chromatin marking and organization 
patterns, or epigenomes. Pluripotent cell epigenomes 
must organize genetic information in a way that 
is compatible with both the maintenance of self-
renewal programs and the retention of multilineage 
differentiation potential. In this review, we give a brief 
overview of the recent technological advances in 
genomics that are allowing scientists to characterize 
and compare epigenomes of different cell types at an 
unprecedented scale and resolution. We then discuss 
how utilizing these technologies for studies of hESCs 
has demonstrated that certain chromatin features, 
including bivalent promoters, poised enhancers, and 
unique DNA modification patterns, are particularly 
pervasive in hESCs compared with differentiated cell 
types. We outline these unique characteristics and 
discuss the extent to which they are recapitulated 
in iPSCs. Finally, we envision broad applications 
of epigenomics in characterizing the quality and 
differentiation potential of individual pluripotent lines, 
and we discuss how epigenomic profiling of regulatory 
elements in hESCs, iPSCs and their derivatives can 
improve our understanding of complex human 
diseases and their underlying genetic variants.
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© 2011 BioMed Central LtdTechnological advances have made the exploration of 
epigenomes  feasible  in  a  rapidly  increasing  number  of 
cell types and tissues. Systematic efforts at such analyses 
had  been  undertaken  by  the  human  ENCyclopedia  Of 
DNA  Elements  (ENCODE)  and  NIH  Roadmap 
Epigenomics  projects  [20,21].  These  and  other  studies 
have  already  produced,  and  will  generate  in  the  near 
future,  an  overwhelming  amount  of  genome-wide 
datasets  that  are  often  not  readily  comprehensible  to 
many  biologists  and  physicians.  However,  given  the 
importance of epigenetic patterns in defining cell identity, 
understanding  and  utilizing  epigenomic  mapping  will 
become a necessity in both basic and translational stem 
cell  research.  In  this  review,  we  strive  to  provide  an 
overview of the main concepts, technologies and outputs 
of epigenomics in a form that is accessible to a broad 
audience. We summarize how epigenomes are studied, 
discuss  what  we  have  learned  so  far  about  unique 
epigenetic properties of hESCs and iPSCs, and envision 
direct  implications  of  epigenomics  in  translational 
research and medicine.
Technological advances in genomics and 
epigenomics
Epigenomics is defined here as genomic-scale studies of 
chromatin  regulatory  variation,  including  patterns  of 
histone  PTMs,  DNA  methylation,  nucleosome 
positioning  and  long-range  chromosomal  interactions. 
Over  the  past  20  years,  many  methods  have  been 
developed to probe different forms of this variation. For 
example,  a  plethora  of  antibodies  recognizing  specific 
histone  modifications  has  been  developed  and  used  in 
chromatin  immunoprecipitation  (ChIP)  assays  for 
studying the local enrichment of histone PTMs at specific 
loci  [22,23].  Similarly,  bisulfite-sequencing  (BS-seq)-
based,  restriction  enzyme-based  and  affinity-based 
approaches  for  analyzing  DNA  methylation  have  been 
established  [24,25],  in  addition  to  methods  to  identify 
genomic  regions  with  low-nucleosomal  content  (for 
example,  DNAse  I  hypersensitivity  assay)  [26]  and  to 
probe  long-range  chromosomal  interactions  (such  as 
chromosomal conformation capture or 3C [27]).
Although  these  approaches  were  first  established  for 
low-  to  medium-throughput  studies  (for  example, 
interrogation of a selected subset of genomic loci), recent 
breakthroughs  in  next-generation  sequencing  have 
allowed  rapid  adaptation  and  expansion  of  existing 
technologies  for  genome-wide  analyses  of  chromatin 
features with an unprecedented resolution and coverage 
[28-44]. These methodologies include, among others, the 
ChIP-sequencing  (ChIP-seq)  approach  to  map  histone 
modification  patterns  and  occupancy  of  chromatin 
modifiers  in  a  genome-wide  manner,  and  MethylC 
sequencing  (MethylC-seq)  and  BS-seq  techniques  for 
large-scale  analysis  of  DNA  methylation  at  single-
nucleotide resolution. The main epigenomic technologies 
have  been  reviewed  recently  [45-47]  and  are  listed  in 
Table 1. The burgeoning field of epigenomics has already 
begun  to  reveal  the  enormous  predictive  power  of 
chromatin  profiling  in  annotating  functional  genomic 
elements  in  specific  cell  types.  Indeed,  chromatin 
signatures that characterize different classes of regulatory 
elements, including promoters, enhancers, insulators and 
long non-coding RNAs, have been uncovered (summarized 
in Table 2). Additional signatures that further specify and 
distinguish unique classes of genomic regulatory elements 
are likely to be discovered over the next few years. In the 
following  section  we  summarize  epigenomic  studies  of 
hESCs  and  pinpoint  unique  characteristics  of  the 
pluripotent cell epigenome that they reveal.
Epigenomic features of hESCs
ESCs  provide  a  robust,  genomically  tractable  in  vitro 
model to investigate the molecular basis of pluripotency 
and embryonic development [1,2]. In addition to sharing 
many fundamental properties with chromatin of somatic 
Table 1. Next-generation sequencing-based methods used 
in epigenomic studies
Epigenetic modification  Method  Reference(s)
DNA methylation  MethylC-seq  [40]
  BS-seq  [31]
  MeDIP-seq  [33]
  MRE-seq  [37]
  MethylCap-seq  [30]
  RRBS  [41]
Histone post-translational modifications  ChIP-seq  [22,42]
Histone variants  ChIP-seq  [36]
Chromatin modifiers and remodelers  ChIP-seq  [38,43]
Chromatin accessibility  DNAseI-seq  [29]
  FAIRE-seq  [35]
  Sono-seq  [28]
Nucleosome positioning and turnover  MNase-seq  [44]
  CATCH-IT  [32]
Long-range chromatin interactions  Hi-C  [39]
  ChIA-PET  [34]
Allele-specific chromatin signatures  haploChIP  [42,97,124]
BS-seq, bisulfite sequencing; CATCH-IT, covalent attachment of tags to capture 
histones and identify turnover; ChIA-PET, chromatin interaction analysis 
with paired-end tag sequencing; ChIP-seq, chromatin immunoprecipitation 
sequencing; DNAseI-seq, DNAseI sequencing; FAIRE-seq, formaldehyde-assisted 
isolation of regulatory elements sequencing; haploChIP, haplotype-specific 
ChIP; Hi-C, high-throughput chromosome capture; MeDIP-seq, methylated DNA 
immunoprecipitation sequencing; MethylCap-seq, MethylCap sequencing; 
MethylC-seq, MethylC sequencing; MNase-seq, micrococcal nuclease 
sequencing; MRE-seq, methylation-sensitive restriction enzyme sequencing; 
RRBS, reduced representation bisulfite sequencing; Sono-seq, sonicated 
chromatin sequencing.
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unique features, such as the increased mobility of many 
structural  chromatin  proteins,  including  histones  and 
heterochromatin  protein  1  [48],  and  differences  in 
nuclear  organization  suggestive  of  a  less  compacted 
chromatin structure [48-51]. Recent epigenomic profiling 
of  hESCs  has  uncovered  several  characteristics  that, 
although  not  absolutely  unique  to  hESCs,  appear 
particularly  pervasive  in  these  cells  [52-54].  Below,  we 
focus on these characteristics and their potential role in 
mediating the epigenetic plasticity of hESCs.
Bivalent domains at promoters
The term ‘bivalent domains’ is used to describe chromatin 
regions  that  are  concomitantly  modified  by  the 
trimethylation  of  lysine  4  of  histone  H3  (H3K4me3),  a 
modification  generally  associated  with  transcriptional 
initiation, and trimethylation of lysine 27 of histone H3 
(H3K27me3),  a  modification  associated  with  Polycomb-
mediated  gene  silencing.  Although  first  described  and 
most extensively characterized in mouse ESCs (mESCs) 
[55,56], bivalent domains are also present in hESCs [57,58], 
and in both species they mark transcription start sites of 
key  developmental  genes  that  are  poorly  expressed  in 
ESCs, but induced upon differentiation. Albeit defined by 
the  presence  of  H3K27me3  and  H3K4me3,  bivalent 
promoters are also characterized by other features, such as 
the occupancy of the histone variant H2AZ [59]. Upon 
differentiation,  bivalent  domains  at  specific  promoters 
resolve into a transcriptionally active H3K4me3-marked 
monovalent state, or a transcriptionally silent H3K27me3-
marked  monovalent  state,  depending  on  the  lineage 
commitment  [42,56].  However,  a  subset  of  bivalent 
domains  is  retained  upon  differentiation  [42,60],  and 
bivalently marked promoters have been observed in many 
progenitor  cell  populations,  perhaps  reflecting  their 
remaining  epigenetic  plasticity  [60].  Nevertheless, 
promoter bivalency seems considerably less abundant in 
differentiated cells, and appears to be further diminished 
in unipotent cells [42,54,56]. These observations led to the 
hypothesis  that  bivalent  domains  are  important  for 
pluripotency,  allowing  early  developmental  genes  to 
remain silent yet able to rapidly respond to differentiation 
cues.  A  similar  function  of  promoter  bivalency  can  be 
hypothesized  for  multipotent  or  oligopotent  progenitor 
cell  types.  However,  it  needs  to  be  more  rigorously 
established  how  many  of  the  apparently  ‘bivalent’ 
promoters observed in progenitor cells truly posses this 
chromatin state, and how many reflect heterogeneity of 
the analyzed cell populations, in which some cells display 
H4K4me3-only and others H3K27me3-only signatures at 
specific promoters.
Poised enhancers
In  multicellular  organisms,  distal  regulatory  elements, 
such  as enhancers,  play  a  central  role  in  cell-type  and 
signaling-dependent  gene  regulation  [61,62].  Although 
embedded within the vast non-coding genomic regions, 
active  enhancers  can  be  identified  by  epigenomic 
profiling of certain histone modifications and chromatin 
regulators [63-65]. A recent study revealed that unique 
chromatin  signatures  distinguish  two  functional 
enhancer classes in hESCs: active and poised [66]. Both 
classes  are  bound  by  coactivators  (such  as  p300  and 
BRG1)  and  marked  by  H3K4me1,  but  while  the  active 
class is enriched in acetylation of lysine 27 of histone H3 
(H3K27ac),  the  poised  enhancer  class  is  marked  by 
H3K27me3  instead.  Active  enhancers  are  typically 
associated  with  genes  expressed  in  hESCs  and  in  the 
epiblast,  whereas  poised  enhancers  are  located  in 
proximity to genes that are inactive in hESCs, but which 
play critical roles during early stages of post-implantation 
development  (for  example,  gastrulation,  neurulation, 
early somitogenesis). Importantly, upon signaling stimuli, 
poised enhancers switch to an active chromatin state in a 
lineage-specific manner and are then able to drive cell-
type-specific gene expression patterns. It remains to be 
determined  whether  H3K27me3-mediated  enhancer 
Table 2. Chromatin signatures defining different classes of regulatory elements
Regulatory element  Chromatin signature  Cell type  References
Active promoters  Main: H3K4me3/2. Additional: H3ac, H4ac  General  [42,56,63,64,79]
Poised promoters (bivalent)  Main: H3K4me3/2, H3K27me3. Additional: H2AZ, MacroH2A  More prevalent in ESCs/iPSCs  [42,56,59]
Inactive promoters (CpG island-poor)  meC  General  [41,68,70]
Active enhancers  Presence: p300, H3K4me1/2, H3K27ac. Absence: H3K4me3, H3K27me3  General  [63,64,79]
Poised enhancers  Presence: p300, H3K4me1/2, H3K27me3. Absence: H3K4me3, H3K27ac  Prevalent in hESCs  [66,67]
Insulators  CTCF  General  [105]
Long non-coding RNAs  promoter: H3K4me3. Gene body: H3K36me3  General  [104]
ESC, embryonic stem cell; CTCF, CCCTC-binding factor, insulator associated protein; hESC, human embryonic stem cell; iPSC, induced pluripotent stem cell; H2AZ, 
histone variant H2AZ; H3ac, acetylation of histone H3; H4ac, acetylation of histone H4; H3K4me1/2/3, (mono-, di- and tri) methylation of lysine 4 of histone H3; 
H3K27ac, acetylation of lysine 27 of histone H3; H3K27me3, trimethylation of lysine 27 of histone H3; H3K36me3, trimethylation of lysine 36 of histone H3; MacroH2A, 
histone variant MacroH2A; meC, methylcytosine.
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work  by  Creighton  et  al.  [67]  suggests  that  poised 
enhancers  are  also  present  in  mESCs  and  in  various 
differentiated  mouse  cells,  although  in  this  case  the 
poised  enhancer  signature  did  not  involve  H3K27me3, 
but H3K4me1 only. Nevertheless, our unpublished data 
indicate  that,  similar  to  the  bivalent  domains  at 
promoters, simultaneous H3K4me1/H3K27me3 marking 
at enhancers is much less prevalent in more restricted 
cell types compared with both human and mouse ESCs 
(A Rada-Iglesias, R Bajpai and J Wysocka, unpublished 
observations).  Future  studies  should  clarify  whether 
poised  enhancers  are  marked  by  the  same  chromatin 
signature in hESCs, mESCs and differentiated cell types, 
and evaluate the functional relevance of the Polycomb-
mediated H3K27 methylation at enhancers.
Unique DNA methylation patterns
Mammalian  DNA  methylation  occurs  at  position  5  of 
cytosine  residues,  generally  in  the  context  of  CG 
dinucleotides (that is, CpG dinucleotides), and has been 
associated  with  transcriptional  silencing  both  at 
repetitive DNA, including transposon elements, and at 
gene promoters [13,14]. Initial DNA methylation studies 
of  mESCs  revealed  that  most  CpG-island-rich  gene 
promoters,  which  are  typically  associated  with  house-
keeping  and  developmental  genes,  are  DNA 
hypomethylated,  whereas  CpG-island-poor  promoters, 
typically  associated  with  tissue-specific  genes,  are 
hypermethylated [41,60]. Moreover, methylation of H3K4 
at both promoter-proximal and distal regulatory regions 
is anti-correlated with their DNA methylation level, even 
at CpG-island-poor promoters [60]. Nevertheless, these 
general correlations are not ESC-specific features as they 
have also been observed in a variety of other cell types 
[25,60,68].  On  the  other  hand,  recent  comparisons  of 
DNA  methylation  in  early  pre-  and  postimplantation 
mouse  embryos  with  those  of  mESCs  revealed  that, 
surprisingly,  mESCs  accumulate  promoter  DNA 
methylation  that  is  more  characteristic  of  the 
postimplantation  stage  embryos  rather  than  the 
blastocyst from which they are derived [69].
Although the coverage and resolution of mammalian 
DNA  methylome  maps  have  been  steadily  increasing, 
whole-genome analyses of human methylomes at single-
nucleotide  resolution  require  an  enormous  sequencing 
effort and have been reported only recently [70]. These 
analyses revealed that in hESCs, but not in differentiated 
cells,  a  significant  proportion  (approximately  25%)  of 
methylated  cytosines  are  found  in  a  non-CG  context. 
Non-CG  methylation  is  a  common  feature  of  plant 
epigenomes  [40]  and,  while  it  has  been  previously 
reported  to  occur  in  mammalian  cells  [71],  its 
contribution  to  as  much  as  a  quarter  of  all  cytosine 
methylation  in  hESCs  had  not  been  anticipated.  It 
remains to be established whether non-CG methylation 
in  hESCs  is  functionally  relevant  or,  alternatively,  is 
simply  a  by-product  of  high  levels  of  de  novo  DNA 
methyltransferases and a hyperdynamic chromatin state 
that  characterizes  hESCs  [49,50,72].  Regardless,  its 
prevalence  in  hESC  methylomes  emphasizes  unique 
properties of pluripotent cell chromatin. However, one 
caveat to the aforementioned study and all other BS-seq-
based analyses of DNA methylation is their inability to 
distinguish  between  methylcytosine  (5mC)  and 
hydroxymethylcytosine (5hmC), as both are refractory to 
bisulfite conversion [15,73], and thus it remains unclear 
how much of what has been mapped as DNA methylation 
in fact represents hydroxymethylation.
DNA hydroxymethylation
Another, previously unappreciated modification of DNA, 
hydroxymethylation,  has  become  a  subject  of 
considerable  attention.  DNA  hydroxymethylation  is 
mediated by the TET family enzymes [15], which convert 
5mC to 5hmC. Recent studies have shown that mESCs 
express  high  levels  of  TET  proteins,  and  consequently 
their chromatin is 5hmC-rich [74,75], a property that, to 
date, has only been observed in a limited number of other 
cell  types  –  for  example,  in  Purkinje  neurons  [76]. 
Although the functionality of 5hmC is still unclear, it has 
been  suggested  that  it  represents  a  first  step  in  either 
active  or  passive  removal  of  DNA  methylation  from 
select  genomic  loci.  New  insights  into  5hmC  genomic 
distribution in mESCs have been obtained from studies 
that  utilized  immunoprecipitation  with  5hmC-specific 
antibodies  coupled  to  next-generation  sequencing  or 
microarray  technology,  respectively  [77,78],  revealing 
that a significant fraction of 5hmC occurs within gene 
bodies of transcriptionally active genes and, in contrast 
to  5mC,  also  at  CpG-rich  promoters  [77],  where  it 
overlaps with the occupancy of the Polycomb complex 
PRC2 [78]. Intriguingly, a significant fraction of the intra-
genic 5hmC occurs within a non-CG context [77], which 
prompts investigating whether a subset of the reported 
non-CG methylation in hESCs might actually represent 
5hmC.  Future  studies  should  establish  whether  hESCs 
show  a  similar  5hmC  distribution  to  mESCs.  More 
importantly, it will be essential to re-evaluate the extent 
to  which  cytosine  residues  that  have  been  mapped  as 
methylated in hESCs are indeed hydroxymethylated, and 
to  determine  the  functional  relevance  of  this  novel 
epigenetic mark.
Reduced genomic blocks marked by repressive histone 
modifications
A comprehensive study of epigenomic profiles in hESCs 
and  human  fibroblasts  showed  that,  in  differentiated 
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associated  with  heterochromatin  formation  and  gene 
repression,  such  as  H3K9me2/3  and  H3K27me3,  are 
significantly  expanded  [79].  These  two  histone 
methylation marks cover only 4% of the hESC genome, 
but  well  over  10%  of  the  human  fibroblast  genome. 
Parallel  observations  have  been  made  independently 
in  mice,  where  large  H3K9me2-marked  regions  are 
more frequent in adult tissues in comparison with mESCs 
[80].  Interestingly,  H3K9me2-marked  regions  largely 
overlap  with  the  recently  described  nuclear  lamina-
associated domains [81], suggesting that the appearance 
or  expansion  of  the  repressive  histone  methylation 
marks  might  reflect  a  profound  three-dimensional 
reorganization of chromatin during differentiation [82]. 
Indeed, heterochromatic foci increase in size and number 
upon ESC differentiation, and it has been proposed that 
an ‘open’, hyperdynamic chromatin structure is a crucial 
component of pluripotency maintenance [48-50].
Are hESCs and iPSCs epigenetically equivalent?
Since Yamanaka’s seminal discovery in 2006 showing that 
introduction of the four transcription factors Oct4, Sox2, 
Klf4 and c-Myc is sufficient to reprogram fibroblasts to a 
pluripotent  state,  progress  in  the  iPSC  field  has  been 
breathtaking [4,83,84]. iPSCs have now been generated 
from a variety of adult and fetal somatic cell types using a 
myriad of alternative protocols [3,6,7]. Remarkably, the 
resulting iPSCs seem to share phenotypic and molecular 
properties of ESCs; these properties include pluripotency, 
self-renewal  and  similar  gene  expression  profiles. 
However,  an  outstanding  question  remains:  to  what 
extent are hESCs and iPSCs functionally equivalent? The 
most  stringent  pluripotency  assay,  tetraploid  embryo 
complementation, demonstrated that mouse iPSCs can 
give rise to all tissues of the embryo proper [85,86]. On 
the  other  hand,  many  iPSC  lines  do  not  support 
tetraploid  complementation,  and  those  that  do  remain 
quite  inefficient  in  comparison  with  mESCs  [85,87]. 
Initial  genome-wide  comparisons  between  ESCs  and 
iPSCs focused on gene expression profiles, which reflect 
the transcriptional state of a given cell type, but not its 
developmental  history  or  differentiation  potential 
[4,84,88]. These additional layers of information can be 
uncovered,  at  least  partially,  by  examining  epigenetic 
landscapes.  In  this  section,  we  summarize  studies 
comparing  DNA  methylation  and  histone  modification 
patterns in ESCs and iPSCs.
Sources of variation in iPSC and hESC epigenetic 
landscapes
Bird’s eye view comparisons show that all major features 
of  the  hESC  epigenome  are  re-established  in  iPSCs 
[89,90]. On the other hand, when more subtle distinctions 
are considered, recent studies have reported differences 
between  iPSC  and  hESC  DNA  methylation  and  gene 
expression  patterns  [90-94].  Potential  sources  of  these 
differences  can  be  largely  divided  into  three  groups: 
(i)  experimental  variability  in  cell  line  derivation  and 
culture;  (ii)  genetic  variation  among  cell  lines;  and 
(iii)  systematic  differences  representing  hotspots  of 
aberrant epigenomic reprogramming.
Although differences arising as a result of experimental 
variability  do  not  constitute  biologically  meaningful 
distinctions between the two stem cell types, they can be 
informative when assessing the quality and differentiation 
potential of individual lines [91,95]. The second source of 
variability  is  a  natural  consequence  of  the  genetic 
variation  among  human  cells  or  embryos  from  which 
iPSCs  and  hESCs  are  respectively  derived.  Genetic 
variation  likely  underlies  many  of  the  line-to-line 
differences  in  DNA  and  histone  modification  patterns, 
underscoring the need for using cohorts of cell lines and 
stringent  statistical  analyses  to  draw  systematic 
comparisons  between  hESCs,  healthy  donor-derived 
iPSCs,  and  disease-specific  iPSCs.  In  support  of  the 
significant  impact  of  human  genetic  variation  on 
epigenetic  landscapes,  recent  studies  of  specific 
chromatin  features  in  lymphoblastoid  cells  [96,97] 
isolated from related and unrelated subjects showed that 
individual, as well as allele-specific, heritable differences 
in chromatin signatures can be largely explained by the 
underlying genetic variants. Although genetic differences 
make  comparisons  between  hESC  and  iPSC  lines  less 
straightforward, we will discuss later how these can be 
harnessed  to  uncover  the  role  of  specific  regulatory 
sequence variants in human disease. Finally, systematic 
differences  between  hESC  and  iPSC  epigenomes  may 
arise  through  the  incomplete  erasure  of  marks 
characteristic of the somatic cell type of origin (somatic 
memory) during iPSC reprogramming, or defects in the 
re-establishment of hESC-like patterns in iPSCs, or as a 
result  of  selective  pressure  during  reprogramming  and 
the  appearance  of  iPSC-specific  signatures  [90,98]. 
Regardless  of  the  underlying  sources  of  variation, 
understanding epigenetic differences between hESC and 
iPSC lines will be essential for harnessing the potential of 
these cells in regenerative medicine.
Remnants of the somatic cell epigenome in iPSCs: lessons 
from DNA methylomes
Studies  of  stringently  defined  models  of  mouse 
reprogramming  have  shown  that  cell-type-of-origin-
specific differences in gene expression and differentiation 
potential  exist  in  early  passage  iPSCs,  leading  to  the 
hypothesis that an epigenetic memory of previous fate 
persists  in  these  cells  [98,99].  This  epigenetic  memory 
has been attributed to the presence of residual somatic 
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within  regions  located  outside  of,  but  in  proximity  to, 
CpG islands, at so-called ‘shores’ [98,100]. The incomplete 
erasure  of  somatic  methylation  appears  to  predispose 
iPSCs to differentiation into fates related to the cell type 
of origin, while restricting differentiation towards other 
lineages. Importantly, this residual memory of past fate 
appears to be transient, and diminishes upon continuous 
passaging, serial reprogramming or treatment with small 
molecule  inhibitors  of  histone  deacetylase  or  DNA 
methyltransferase activity [98,99]. These results suggest 
that  remnants  of  somatic  DNA  methylation  are  not 
actively maintained in iPSCs during replication and thus 
can be erased through cell division.
More  recently,  whole-genome,  single-base-resolution 
DNA  methylome  maps  have  been  generated  for  five 
distinct human iPSC lines and compared with those of 
hESCs and somatic cells [90]. That study demonstrated 
that  although  the  hESC  and  iPSC  DNA  methylation 
landscapes  are  remarkably  similar  overall,  hundreds  of 
differentially  methylated  regions  (DMRs)  exist.  Never-
theless, only a small fraction of DMRs represents failure 
in erasure of somatic DNA methylation, whereas the vast 
majority corresponds to either hypomethylation (defects 
in the methylation of genomic regions that are marked in 
hESCs) or the appearance of iPSC-specific methylation 
patterns, not present in hESCs or the somatic cell type of 
origin. Moreover, these DMRs are likely to be resistant to 
passaging,  as  the  methylome  analyses  were  performed 
using relatively late passage iPSCs [80]. Due to a limited 
number of iPSC and hESC lines used in the study, genetic 
and experimental variation among individual lines may 
be a big contributor to the reported DMRs. However, a 
significant subset of DMRs is shared among iPSC lines of 
different genetic background and cell type of origin, and 
is transmitted through differentiation, suggesting that at 
least  some  DMRs  may  represent  non-stochastic  epi-
genomic hotspots that are refractive to reprogramming.
Reprogramming resistance of subtelomeric and 
subcentromeric regions?
In  addition  to  erasing  somatic  epigenetic  marks,  an 
essential  component  of  reprogramming  is  the  faithful 
re-establishment  of  hESC-like  epigenomic  features. 
Although, as discussed above, most of the DNA methyla-
tion  is  correctly  re-established  during  reprogramming, 
large megabase-scale regions of reduced methylation can 
be  detected  in  iPSCs,  often  within  the  vicinity  of 
centromeres  and  telomeres  [90].  Biased  depletion  of 
DNA methylation from subcentromeric and subtelomeric 
regions  correlates  with  blocks  of  H3K9me3  that  mark 
these loci in iPSCs and somatic cells, but not in hESCs 
[79,90].  Aberrant  DNA  methylation  in  proximity  to 
centromeres  and  telomeres  suggests  that  these 
chromosomal territories may have features that render 
them more resistant to epigenetic changes. Intriguingly, 
histone  variant  H3.3,  which  is  generally  implicated  in 
transcription-associated  and  replication-independent 
histone  deposition,  was  recently  found  to  also  occupy 
subtelomeric and subcentromeric regions in mESCs and 
mouse  embryo  [36,101,102].  It  has  been  previously 
suggested  that  H3.3  plays  a  critical  role  in  the 
maintenance  of  transcriptional  memory  during 
reprogramming of somatic nuclei by the egg environment 
(that is, reprogramming by somatic cell nuclear transfer) 
[103],  and  it  is  tempting  to  speculate  that  a  similar 
mechanism  may  contribute  to  the  resistance  of  the 
subtelomeric  and  subcentromeric  regions  to 
reprogramming in iPSCs.
Anticipating future fates: reprogramming at regulatory 
elements
Pluripotent cells are in a state of permanent anticipation 
of  many  alternative  developmental  fates,  and  this  is 
reflected in the prevalence of the poised promoters and 
enhancers in their epigenomes [42,66]. Although multiple 
studies  have  demonstrated  that  bivalent  domains  at 
promoters are re-established in iPSCs with high fidelity 
[89], the extent to which chromatin signatures associated 
with  poised  developmental  enhancers  in  hESCs  are 
recapitulated  in  iPSCs  remains  unclear.  However,  the 
existence  of  a  large  class  of  poised  developmental 
enhancers linked to genes that are inactive in hESCs, but 
involved  in  postimplantation  steps  of  human  embryo-
genesis [66], suggest that proper enhancer rewiring to a 
hESC-like  state  may  be  central  to  the  differentiation 
potential  of  iPSCs.  Defective  epigenetic  marking  of 
developmental enhancers to a poised state may result in 
impaired  or  delayed  ability  of  iPSCs  to  respond  to 
differentiation  cues,  without  manifesting  itself  at  the 
transcriptional  or  promoter  modification  level  in  the 
undifferentiated  state.  Therefore,  we  would  argue  that 
epigenomic profiling of enhancer repertoires should be a 
critical  component  in  evaluating  iPSC  quality  and 
differentiation  potential  (Figure  1)  and  could  be 
incorporated into already existing pipelines [91,95].
Relevance of epigenomics for human disease and 
regenerative medicine
In  this  section,  we  envision  how  recent  advances  in 
epigenomics  can  be  used  to  gain  insight  into  human 
development and disease, and to facilitate the transition 
of stem cell technologies towards clinical applications.
Using epigenomics to predict developmental robustness 
of iPSC lines for translational applications
As discussed earlier, epigenomic profiling can be used to 
annotate functional genomic elements in a genome-wide 
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signatures can distinguish active and poised enhancers 
and promoters, identify insulator elements and uncover 
non-coding  RNAs  transcribed  in  a  given  cell  type 
[42,56,63,64,66,104,105]  (Table  2).  Given  that 
developmental  potential  is  likely  to  be  reflected  in  the 
epigenetic marking of promoters and enhancers linked to 
poised  states,  epigenomic  maps  should  be  more 
predictive  of  iPSC  differentiation  capacity  than 
transcriptome profiling alone (Figure 1). However, before 
epigenomics can be used as a standard tool in assessing 
iPSC and hESC quality in translational applications, the 
Figure 1. Epigenomics as a tool to assess iPSC identity. Chromatin signatures obtained by epigenomic profiling of a cohort of human 
embryonic stem cell (hESC) lines can be used to generate hESC reference epigenomes (left panels). The extent of reprogramming and 
differentiation potential of individual induced pluripotent stem cell (iPSC) lines can be assessed by comparing iPSC epigenomes (right panels) to 
the reference hESC epigenomes. (a-c) Such comparisons should evaluate epigenetic states at regulatory elements of self-renewal genes that are 
active in hESCs (a), developmental genes that are poised in hESCs (b), and tissue-specific genes that are inactive in hESCs, but are expressed in 
the cell type of origin used to derive iPSC (c). H3K4me1, methylation of lysine 4 of histone H3; H3K4me3, trimethylation of lysine 4 of histone H3; 
H3K27ac, acetylation of lysine 27 of histone H3; H3K27me3, trimethylation of lysine 27 of histone H3; meC, methylcytosine.
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although  ChIP-seq  analysis  of  chromatin  signatures  is 
extremely  informative,  its  reliance  on  antibody  quality 
requires  the  development  of  renewable,  standardized 
reagents. Also, importantly, to assess the significance of 
epigenomic  pattern  variation,  sufficient  numbers  of 
reference  epigenomes  need  to  be  obtained  from  hESC 
and iPSC lines that are representative of genetic variation 
and  have  been  rigorously  tested  in  a  variety  of 
differentiation  assays.  The  first  forays  towards  the 
development  of  such  tools  and  resources  have  already 
been made [89,91,106,107].
Annotating regulatory elements that orchestrate human 
differentiation and development
As a result of ethical and practical limitations, we know 
very little about the regulatory mechanisms that govern 
early human embryogenesis. hESC-based differentiation 
models offer a unique opportunity to isolate and study 
cells  that  correspond  to  transient  progenitor  states 
arising  during  human  development.  Subsequent 
epigenomic  profiling  of  hESCs  that  have  been 
differentiated in vitro along specific lineages can be used 
to  define  the  functional  genomic  regulatory  space,  or 
‘regulatome’,  of  a  given  cell  lineage  (Figure  2a).  This 
approach  is  particularly  relevant  for  genome-wide 
identification of tissue-specific enhancers and silencers, 
which are highly variable among different, even closely 
related,  cell  types.  Characterizing  cell-type-specific 
regulatomes  will  be  useful  for  comparative  analyses  of 
gene  expression  circuitries.  In  addition,  through 
bioinformatic analysis of the underlying DNA sequence, 
they can be used to predict novel master regulators of 
specific cell fate decisions, and these can then serve as 
candidates  in  direct  transdifferentiation  approaches. 
Moreover,  mapping  enhancer  repertoires  provides  an 
enormous resource for the development of reporters for 
isolation  and  characterization  of  rare  human  cell 
populations, such as the progenitor cells that arise only 
transiently in the developmental process [66]. Ultimately, 
this  knowledge  will  allow  refinement  of  the  current 
differentiation protocols and derivation of well-defined, 
and  thus  safer  and  more  appropriate,  cells  for 
replacement  therapies  [3,108-110].  Furthermore,  as 
discussed  below,  characterizing  cell-type  specific 
regulatomes  will  be  essential  for  understanding  non-
coding variation in human disease.
Cell-type-specific regulatomes as a tool for understanding 
the role of non-coding mutations in human disease
During  the  past  few  years,  genome-wide  association 
studies have dramatically expanded the catalog of genetic 
variants  associated  with  some  of  the  most  common 
human disorders, such as various cancer types, type 2 
diabetes, obesity, cardiovascular disease, Crohn’s disease 
and cleft lip/palate [111-118]. One recurrent observation 
is  that  most  disease-associated  variants  occur  in  non-
coding parts of the human genome, suggesting a large 
non-coding component in human phenotypic variation 
and disease. Indeed, several studies document a critical 
role for genetic aberrations occurring within individual 
distal  enhancer  elements  in  human  pathogenesis  [119-
121]. To date, the role of regulatory sequence mutation in 
human  disease  has  not  been  systematically  examined. 
However,  given  the  rapidly  decreasing  cost  of  high-
throughput sequencing and the multiple disease-oriented 
whole genome sequencing projects that are under way, 
the next years will bring the opportunity and challenge to 
ascribe functional significance to disease-associated non-
coding mutations [122]. Doing so will require both an 
ability to identify and obtain cell types relevant to disease, 
and the ability to characterize their specific regulatomes.
We envision that combining pluripotent cell differentia-
tion  models  with  epigenomic  profiling  will  provide  an 
important  tool  for  uncovering  the  role  of  non-coding 
mutations in human disease. For example, if the disease 
of interest affects a particular cell type that can be derived 
in  vitro  from  hESCs,  characterizing  the  reference 
regulatome  of  this  cell  type,  as  described  above,  will 
shrink the vast genomic regions that might be implicated 
in disease into a much smaller regulatory space that can 
be more effectively examined for recurrent variants that 
are associated with disease (Figure 2a). The function of 
these regulatory variants can be further studied using in 
vitro and in vivo models, of which iPSC-based ‘disease in 
a dish’ models appear particularly promising [123]. For 
example,  disease-relevant  cell  types  obtained  from 
patient-derived and healthy-donor-derived iPSCs can be 
used to study the effects of the disease genotype on cell-
type-specific  regulatomes  (Figure  2b).  Moreover,  given 
that many, if not most, regulatory variants are likely to be 
heterozygous  in  patients,  loss  or  gain  of  chromatin 
features  associated  with  those  variants  (such  as  p300 
binding, histone modifications and nucleosome occupancy) 
can be assayed independently for each allele within the 
same iPSC line. Indeed, allele-specific sequencing assays 
are  already  being  developed  [42,96,97,124]  (Table  1). 
Moreover,  these  results  can  be  compared  with  allele-
specific RNA-seq transcriptome analyses from the same 
cells [125], yielding insights into the effects of disease-
associated regulatory alleles on the transcription of genes 
located in relative chromosomal proximity [96,125].
Conclusions and future perspective
Analyses of hESC and iPSC chromatin landscapes have 
already provided important insights into the molecular 
basis of pluripotency, reprogramming and early human 
development.  Our  current  view  of  the  pluripotent  cell 
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Page 8 of 13Figure 2. The combination of stem cell models and epigenomics in studies of the role of non-coding mutations in human disease. 
Epigenomic analyses of cells derived through in vitro stem cell differentiation models can be used to define the functional regulatory space, or 
‘regulatome’, of a given cell type and to study the significance of the non-coding genetic variation in human disease. (a) The vast non-coding 
fraction of the human genome can be significantly reduced by defining the regulatome of a given cell type via epigenomic profiling of chromatin 
signatures that define different types of regulatory elements, such as enhancers, promoters and insulators. Regulatome maps obtained in the 
disease-relevant cell types define genomic space that can be subsequently searched for the recurrent disease-associated genetic variants. (b) Most 
genetic variants associated with complex human diseases appear to reside in non-coding regions of the human genome. To assess functional 
consequences of such variants, disease-relevant cell types can be derived from healthy and disease-affected donor induced pluripotent stem 
cells (iPSCs) and epigenomic profiling can be used to evaluate how these genetic variants affect chromatin signatures, and transcription factor 
and coactivator occupancy at regulatory elements. CTCF, CCCTC-binding factor, insulator associated protein; ESC, embryonic stem cell; H3K4me1, 
methylation of lysine 4 of histone H3; H3K4me3, trimethylation of lysine 4 of histone H3; H3K27ac, acetylation of lysine 27 of histone H3; H3K27me3, 
trimethylation of lysine 27 of histone H3; meC, methylcytosine.
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Page 9 of 13epigenome  has  been  largely  acquired  due  to  recent 
advances  in  next-generation  sequencing  technologies, 
such  as  ChIP-seq  or  MethylC-seq.  Several  chromatin 
features, including bivalent promoters, poised enhancers 
and  pervasive  non-CG  methylation  seem  to  be  more 
abundant in hESCs compared with differentiated cells. It 
will  be  important  in  future  studies  to  dissect  the 
molecular  function  of  these  epigenomic  attributes  and 
their relevance for hESC biology. Epigenomic tools are 
also being widely used in the evaluation of iPSC identity. 
In  general,  the  epigenomes  of  iPSC  lines  seem  highly 
similar  to  those  of  hESC  lines,  albeit  recent  reports 
suggest  that  differences  in  DNA  methylation  patterns 
exist between the two pluripotent cell types. It will be 
important to understand the origins of these differences 
(that  is,  somatic  memory,  experimental  variability, 
genetic  variation),  as  well  as  their  impact  on  iPSC 
differentiation  potential  or  clinical  applications. 
Moreover, additional epigenetic features other than DNA 
methylation should be thoroughly compared, including 
proper re-establishment of poised enhancer patterns. As 
a  more  complete  picture  of  the  epigenomes  of  ESCs, 
iPSCs  and  other  cell  types  emerges,  important  lessons 
regarding early developmental decisions in humans will 
be  learnt,  facilitating  not  only  our  understanding  of 
human development, but also the establishment of robust 
in  vitro  differentiation  protocols.  These  advancements 
will in turn allow for generation of replacement cells for 
cellular transplantation approaches and for development 
of the appropriate ‘disease in a dish’ models. Within such 
models, epigenomic profiling could be especially helpful 
in  understanding  the  genetic  basis  of  complex  human 
disorders,  where  most  of  the  causative  variants  are 
predicted to occur within the vast non-coding fraction of 
the human genome.
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